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Benefits and safety on statins have been well established over 20 years of research. Despite this, the 
vast majority of patients are not adequately treated and do not achieve the low-density lipoprotein 
cholesterol target levels. This is mainly due to poor adherence, which is associated with dangerous 
and sometimes fatal outcomes.   
To increase adherence and prevent worse outcomes, a combination therapy with lower dosage of 
statins and new lipid lowering drugs may be used. However, the implementation of new lipid 
lowering drugs in European countries is still at the beginning.  
For these reasons, aim of this position paper is to give an up-to-date indication from the European 
Society of Cardiology in order to discuss the barriers towards statins adherence and new lipid 
lowering drugs implementation in Europe. 
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Statins have a documented efficacy in lowering low-density lipoprotein cholesterol (LDL-C) levels 
and, also, in improving primary and secondary cardiovascular endpoints. Benefits of statin 
treatment in cardiovascular and non-cardiovascular patients have been fully acknowledged (1-4).  
As such, statins have a Class 1A recommendation for hypercholesterolaemia according to the 
European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guidelines for 
the management of dyslipidaemias (4). In particular, statins should be prescribed to the highest 
therapeutic possible dose to reach the target level (5). Nevertheless, statin therapy initiation is 
challenging as high-dose statins are infrequently prescribed at discharge and use rates are even 
lower by one year after discharge (6). Thus, statins are underused and underdosed (7-8).   
Also, adherence to guideline-recommended statin therapy is far from optimal, and LDL-C targets 
are not achieved in up to 80% of high-risk patients (9-12). Barriers to statin therapy implementation 
are shown in Figure 1. The main barrier is poor adherence to statin therapy,  that is associated with 
a significantly increased risk of cardiovascular events and mortality. Statin intolerance is associated 
with an increased risk for recurrent myocardial infarction and coronary heart disease events  (13).  
 
Taking into account these issues, a multidisciplinary panel of leading international experts has been 
organised by the ESC to discuss the latest evidence, ongoing research and controversial issues 
regarding statins non-adherence and to discuss the barriers of implementation of new-lipid lowering 
drugs in Europe. This executive document reflects the key points of the ESC consensus meeting. 
 
Definitions 
Whilst the term “compliance” has been used historically to indicate a somewhat paternalistic view 
of the doctor-patient relationship (“The patient is simply to do what I tell to do.”) (14), “adherence” 
to treatment is considered as the extent to which the patient continues an agreed-upon mode of 











Adherence is therefore defined as the extent to which a patient’s behaviour—taking medication or 
changing lifestyle—corresponds with agreed recommendations from a healthcare provider (15). 
Regarding taking medications, adherence is composed by at least three components: initiation of 
treatment, execution of treatment, and persistence of treatment over time (15). The last component, 
“persistence”, refers to the act of continuing the treatment for the prescribed duration (8, 16). 
When non-adherence occurs at the beginning, it may imply poor acceptance and therefore non-
initiation of the therapeutic plan. Delayed or omitted drug intake leads to poor execution. Finally, 
intermittent or permanent discontinuation leads to poor persistence (17).  
 
Consequences of statins non adherence 
Non adherence is the most important modifiable factor that compromises treatment outcomes (18) 
and has devastating clinical consequences. In outpatients with stable coronary heart disease (19), 
non-adherence was associated with a greater than two-fold increased rate of subsequent 
cardiovascular events, more than four times increased risk of stroke and almost a four-fold 
increased risk of death. 
Accordingly, adherence to drug therapy may be a surrogate marker for overall healthy behavior. In 
fact, a meta-analysis showed that good adherence to placebo was associated with lower mortality, 
supporting the existence of the “healthy adherer” effect (20). Consistently, a study (21) showed that 
statin-adherent patients were half as likely to experience a subsequent myocardial infarction. In 
younger patients (<65 years) this reduction in myocardial infarction rates was even greater. 
 
Largely due to increased hospitalisations, non adherence is also costly for the healthcare system.  
Thus, for all these reasons, monitoring and promoting adherence to statin therapy is a priority. A 
comprehensive approach is needed in order to increase statin adherence (8, 22). 
 











Common factors leading to statin non adherence and suggested strategies are shown in table 1.  
At the beginning of the treatment, if the patient shows unwillingness to start statin therapy, the 
clinician is recommended to provide counsel about the risks of myocardial infarction and stroke, in 
order to offer education and support to the patient. Indeed, misperception regarding the risks and 
benefits of statin treatment is a common factor of non adherence (23). 
In the case of early discontinuation, a re-counseling should be provided as well. Of note, adherence 
to statin treatment drops over time, particularly when treating the asymptomatic patient. In fact, the 
most common pattern of non-adherence to statin therapy is observable at 1 month of treatment, 
when the target level is reached (8). At 6 months, nearly 50% of primary prevention patients have 
already stopped therapy (24). To prevent this pattern, it may be useful to schedule the re-counseling 
sessions (25, 26). Finally, since coronary events may occur, residual risk should be addressed in 
secondary prevention. 
Therefore, to avoid discontinuation, educational support from the healthcare provider is suggested. 
 
One of the principal reasons for statin discontinuation is myalgia (27). This is a serious and 
apparently common side effect of statins, affecting up to 25% of patients (27). In this case, the 
clinician is recommended to check for causality. Indeed, many of the self-reported muscle 
symptoms are not actually attributable to statins. This has been proven by clinical trials, suggesting 
that myalgia is also frequently reported in placebo groups (28). Thus, the presence of myalgia as a 
nocebo effect may be linked to patient’s negative expectations due to knowledge of statin side-
effects. The ongoing series of randomised controlled “N-of-1” trials comparing atorvastatin and 
placebo in UK primary care will help further elucidate this issue (29). As demonstrated by the 
ODYSSEY LONG TERM (Long-term Safety and Tolerability of Alirocumab Versus Placebo on 
Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia) 
trial (30), side effects may not occur if patients are blind about treatment. This suggests that 











One approach is that patients should be unaware of muscle pain, to avoid discontinuation, and 
future guidelines should keep into account these considerations. 
 
Of note, the panel agrees that “true” (i.e. cause-effect) correlation between muscle pain and statin 
use is very uncommon (1%) and that statin intolerance may be therefore a subjective phenomenon. 
As recently pointed out by the ESC working group on Cardiovascular Pharmacotherapy (8), and by 
further studies (31, 32), a minority of patients is truly statin intolerant.  
When an established and documented link between statin therapy and myalgia is set, the clinician is 
asked to re-challenge with a second statin. If suspected statin intolerance is confirmed on statin 
rechallenge, achieving guideline-recommended LDL-C goals with other drugs than statins is 
indicated (8). Clinically relevant statin-related muscle symptoms should be proven with at least 
three different statins, so patients will be offered therapeutic regimens to adequately prevent their 
cardiovascular risk (27). If this approach is not successful, other combinations may be prescribed. 
However, many experts suggest to start the therapeutic plan with a combination therapy in order to 
avoid problems linked to therapeutic interchange, typically observed with a stepwise approach. 
 
Combination therapy with new lipid lowering drugs: ezetimibe  
Combination therapies present different advantages as elsewhere reviewed (33). First, they have a 
synergistic effect, thus the efficacy is thought to be higher compared to the sum of single drugs. 
Second, they have less adverse events and are therefore are better tolerated. Last but not least, the 
simplified drug regimen usually leads to better adherence and, potentially, better outcomes and 
costs reduction for the healthcare. 
As shown by clinical trials (34-36), statins combined with ezetimibe, a nonstatin drug lowering 
intestinal cholesterol absorption, reduce LDL-C and cardiovascular events. For this reason, 













Use of ezetimibe in patients who are not at target 
The consensus panel debated on whether adding ezetimibe to statin in patients who are not at target 
allows to reach the target with no/ less adverse events (i.e. myalgia). 
The ACTE (A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate the Efficacy 
and Safety of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients 
With Hypercholesterolemia at Risk for Coronary Heart Disease) study (37) evaluated the safety and 
efficacy of ezetimibe added to stable rosuvastatin therapy versus up-titration of rosuvastatin in 
patients with hypercholesterolemia. The trial found that compared to up-titration of the rosuvastatin 
dose, ezetimibe 10 mg primarily added to stable rosuvastatin 5 mg or 10 mg produced greater 
improvements in lipid profile, with better achievement of the LDL-C goals. 
Similarly, the I-ROSETTE (Ildong ROSuvastatin & ezETimibe for hypercholesTElolemia) trial 
(38) an 8-week, phase III, multicenter, randomised, double-blind, active comparator clinical trial, 
compared the efficacy and safety of several combinations with ezetimibe and rosuvastatin versus 
those of rosuvastatin monotherapy in patients with hypercholesterolemia. Patients were randomly 
assigned to receive ezetimibe 10 mg/rosuvastatin 20 mg, ezetimibe 10 mg/rosuvastatin 10 mg, 
ezetimibe 10 mg/rosuvastatin 5 mg, rosuvastatin 20 mg, rosuvastatin 10 mg, or rosuvastatin 5 mg. 
The study found that all the fixed-dose combinations of ezetimibe/rosuvastatin significantly 
improved lipid profiles in patients with hypercholesterolemia compared with rosuvastatin 
monotherapy. In particular, all groups treated with ezetimibe/rosuvastatin reported a decrease in 
mean LDL-C level >50% from baseline values. The safety and tolerability of ezetimibe/rosuvastatin 
therapy were comparable with those of rosuvastatin monotherapy.  
These data have been confirmed also in non-ST elevation acute coronary syndrome by a 
randomised trial (39) investigating whether intermediate-intensity dosage statins combined with 











of rosuvastatin 10mg/ezetimibe 10mg was superior to rosuvastatin 20mg or 10mg with a greater 
effect on lowering LDL-C and a lower incidence of drug-related adverse events. 
 
Use of ezetimibe in high-risk patients 
A question arises as for the use of add-on ezetimibe to statins in specific subgroups who are already 
at target, such as high risk patients or those with comorbidities. To this aim, the IMPROVE-IT 
(IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) (40) investigated the 
efficacy of ezetimibe in patients stratified by TIMI (Thrombolysis In Myocardial Infarction) risk 
score, showing that high-risk patients had the greatest benefit from the addition of ezetimibe to 
statin therapy on the primary composite endpoint (cardiovascular death, myocardial infarction, 
stroke, hospital admission, and coronary revascularisation). Further, the benefit of adding ezetimibe 
to statin was shown to be greater in patients with diabetes mellitus and also, in high-risk patients 
without diabetes (41). No gender-related differences were observable in terms of benefits of adding 
ezetimibe to statin (42). Notably, patients achieving an LDL-C level less than 30 mg/dL at 1 month 
had the lowest rate of cardiovascular events over a 6-year period compared with patients achieving 
higher LDL-C levels, but with similar safety profiles (43). These results provide reassurance 
regarding the longer-term safety and efficacy of the further lowering of LDL-C concentrations 
below the standard 30 mg/dL level in higher-risk patients.   
The consensus panel therefore agrees that data so far available support the use of intensive 
combination lipid-lowering therapy with ezetimibe and statin to improve cardiovascular outcomes, 
with a good safety profile, also in high-risk subgroups who are already at target. From these results, 
the panel suggests to stratify patients according to the risk and then lower LDL-C less than 30 
mg/dL as a beneficial strategy in high risk patients. 
  











The final question is whether there is advantage or not by using a fixed combination 
ezetimibe/statin therapy on patient adherence. We know that adherence decreases with increasing 
number of pills, and this may be common in patients after a coronary acute event. A retrospective 
study (44) in patients with concomitant antihypertensive and lipid-lowering therapy found a greater 
adherence in those initiating the two therapies together, suggesting that a fixed combination may 
improve adherence to treatment.  
 
In conclusion, fixed combination ezetimibe/statin increases LDL-C control, reduces adverse effects 
and may also improve adherence, which is a major determinant of good outcomes. 
 
Combination therapy with PCSK9 inhibitors  
In patients with high risk for cardiovascular disease, the 2016 ESC/EAS guidelines (4) 
recommended treatment with a statin in combination with a cholesterol absorption inhibitor or 
proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Inhibition of the PCSK9 enzyme 
has been shown to lower LDL-C, potentially reducing cardiovascular risk. As elsewhere reviewed 
(45, 46), the approved PCSK9 inhibitors (evolocumab and alirocumab) are effective in reducing 
plasma LDL-C values by 50 to 60%, and in reducing cardiovascular event risk. Also, it has been 
ascertained that the use of evolocumab on top of statin is not associated with cognitive deficits, as 
shown by the EBBINGHAUS (Evaluating PCSK9 Binding antiBody Influence oN coGnitive 
HeAlth in High cardiovascUlar Risk Subjects) trial (47) A meta-analysis (48) demonstrated that 
both alirocumab and evolocumab improved cardiovascular outcomes with good safety profiles. 
Consistently, the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in 
Subjects with Elevated Risk) trial (49) showed that add-on therapy with evolocumab significantly 
lowered LDL-C levels and reduced the risk of cardiovascular events in patients with atherosclerotic 
cardiovascular disease. Again, the trial also showed that patients had a benefit from lowering LDL 











inhibitors added to medium- to high-intensity statin therapy significantly reduced LDL-C in patients 
requiring further LDL-C reduction.  
Similarly, the ODYSSEY ESCAPE (Study of Alirocumab in Patients With Heterozygous Familial 
Hypercholesterolemia Undergoing Low-density Lipoprotein Apheresis Therapy) trial (51), 
evaluating the effect of alirocumab on the rate of standard apheresis treatments in heterozygous 
familial hypercholesterolaemia, showed that alirocumab significantly reduced requirement for 
apheresis. The latter was deferred if LDL-C was at least 30% lower than the baseline (pre-
apheresis) value.  
A sub-analysis of the ODYSSEY COMBO II (52) found that alirocumab was more effective in 
reducing LDL-C levels than ezetimibe in high-risk cardiovascular patients, regardless the presence 
of diabetes mellitus. Similarly, the recent sub-analysis of the ODYSSEY Japan trial (53), in high-
risk patients with hypercholesterolemia on stable statin therapy, found that alirocumab led to 
substantial and sustained LDL-C reductions over time, regardless the diabetes mellitus status at 
baseline. 
A sub-study of the ODYSSEY-KT (54) confirmed the efficacy of alirocumab in improving lipid 
profile, in patients with hypercholesterolemia and high cardiovascular risk. 
These results are consistent with the sub-analysis of the BIOSTAT-CHF (Biology Study to 
Tailored Treatment in Chronic Heart Failure) (55), a multicenter, multinational, prospective, 
observational study that included patients with worsening HF signs and/or symptoms. This sub-
analysis found that PCSK9-LDLR axis was associated with HF outcomes, confirming its role as a 
risk predictor and biotarget in this population. 
Accordingly, the GLAGOV trial (Global Assessment of Plaque Regression With a PCSK9 
Antibody as Measured by Intravascular Ultrasound) (56) showed that evolocumab not only reduced 
LDL-C but also led to greater plaque regression. 
Finally, in patients with statin intolerance, the GAUSS-3 (Goal Achievement after Utilizing an anti-











greater reduction in LDL-C than ezetimibe, with lower occurrence of myalgia and consequent lower 
discontinuation rate for muscle symptoms. Thus, PCSK9 inhibitors may offer a new, safe treatment 
option in patients with statin intolerance (45).  
However, to draw recommendations, results of the phase 3 outcome trials are needed. Now both the 
aforementioned FOURIER trial (49) and the ODYSSEY OUTCOMES (Evaluation of 
Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) 
(57) trial have been published. Both trials were positive with a relative risk reduction of about 15% 
- over statins in the control arm - for the majority of important endpoints. 
 
Recommendations on the use of new lipid lowering drugs 
The use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to 
attain the low-density lipoprotein cholesterol targets is recommended (27). Future guidelines should 
point out that using a fixed combination with new lipid lowering drugs is recommended to lower 
the dose of statins, minimise the side effects and therefore improve adherence without reducing 
efficacy. To this aim, a single-pill administration is recommended. 
As a first step, we advise to stratify patients, following the results of the aforementioned trials, 
showing that high risk patients benefit from higher reductions in LDL levels (<30 mg/dl). As such, 
it is also recommended to personalise the treatment according to the risk. Concordant with new US 
guidelines, a revaluation of correct LDL target (especially in patients at high risk profile) has 
always been advocated in the European guidelines (4, 5). More stringent targets for high risk 
patients have been recommended by the 2019 ESC/EAS Practice Guidelines for the Treatment of  
Dyslipidaemias. The central rationale of lipid therapy is: the higher the patients risk the lower his 
LDL-C goal. This means that a patient at very high risk should receive treatment that is able to 
attain the risk-related goal.  
Two cornerstones for lowering LDL-C intensively are the establishment of LDL-C as a causal 











safety of going very low as has been demonstrated by the recent PCSK9 inhibitor trials, FOURIER , 
EBBINGHOUSE, and ODYSSEY OUTCOMES. Now, LDL particles are considered as a toxin, 
and radical reduction of a toxin is only logical. 
The strategies proposed in this article are in close line with the new Guidelines. On the way to attain 
the LDL-C goal of 1.4 mmol/l (55 mg/dl) in very high risk patients, it is preferable to use the oral 
combination immediately after an event. This reduces the steps of treatment intensifications. An 
even lower goal is recommended for patients with recurrent events: LDL-C <1.0 mmol/L (40 
mg/dl). Also from a practical view-point this is very important for the implementation of the 
treatment, the more steps the more barriers to reach the patient. This is also cost-effective, as is the 
full use of oral lipid lowering therapy if it (only slightly) reduces the need for monoclonal antibody 
therapy. Our proposals here therefore are not only consistent with the new guidelines but also try to 
facilitate their implementation. 
An unsolved issue regards the difficult implementation of the new lipid lowering drugs in clinical 
practice mainly due to the lack of regulations in many EU countries. Strict regulatory indications 
(e.g. family history of hypercholesterolemia for PCSK9) also hinder their clinical use. Last but not 
least, in some EU countries there is no reimbursement for the new lipid lowering drugs and this is a 
further barrier for their implementation, in particular for PCSK9 inhibitors.  
More awareness is therefore needed in medical community to overcome these barriers.   
Finally, it is well-known that lifestyle modifications may improve plasma lipid profile, as 
acknowledged by the guidelines. In particular, the role of dietary measures in the management of 
dyslipidaemia is pivotal and, as such, a multidisciplinary approach also targeted at correcting 
nutrition is recommended.   
 
Future research: nutraceuticals 
In light of their lipid-lowering and beyond lipid-lowering effects, certain nutraceuticals have been 











berberine, artichoke, soluble fiber, and plant sterols and stanols have been studied alone or in 
combination with each other, as well as with ezetimibe. Unfortunately, there are still few data to 
draw firm conclusions about their long-term safety and efficacy. Their effects and available data are 
summarised elsewhere (58).  
In particular, there is randomised evidence supporting the efficacy of plant sterol ester supplements 
in improving lipid profile, by lowering plasma cholesterol levels, and consequently reducing 
cardiovascular risk (59-61). When more pharmacological data on the long-term efficacy and safety 
of these nutraceuticals will be collected, scientific societies will be asked to provide regulations and 
recommendations on their use in statin intolerant patients.  
 
Conclusions 
Non adherence should be considered as a dangerous and sometimes fatal risk factor.  
It is pivotal to distinguish between statin intolerance and non adherence due to statin reluctance. 
Adherence is modifiable and predictable, and as such it may be prevented and even reversed.  
To this aim, fixed combinations with new lipid lowering drugs are going to change our clinical 
practice. In particular, combination with lower dose statin and ezetimibe in the same pill is one of 
the best strategies in terms of efficacy and adherence. No safety concern has been raised for the new 
lipid lowering medication, including cognitive impairment. However, longer follow ups are 
warranted.  
 













Main barriers to statin therapy implementation. 
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Table 1. Factors leading to non-adherence to statin treatment  
  
Causes Suggested strategies to improve adherence 
Complexity of treatment, polypharmacy  
Frequency and duration of treatment 
Frequent changes in treatment 
Cost of medication 
Other therapy-related factors 
 
Single pill administration 
Patient has been told about side effects 
Patient’s misperception  
Lack of benefit in treatment OR immediacy of 
beneficial effects 
Lack of access to care or medication 
Poor relationship patient-doctor 
 
Improve patient awareness and doctor-patient 
relationship  
Increase availability of medical support  
 
Psychological problems, cognitive impairment 
  
Role of caregivers 
Inadequate follow up or discharge planning  
 
Implementation of treatment plan 
Statin-specific, documented side effects 
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